RAPT Therapeutics, Inc. (RAPT)

4.3700 +0.0400 (+0.92%) 市場開市。 截至 03:29PM EDT。

RAPT Therapeutics, Inc.

561 Eccles Avenue
South San Francisco, CA 94080
United States
650 489 9000
https://www.rapt.com

版塊: Healthcare
行業: Biotechnology
全職員工: 126

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Brian Russell Wong M.D., Ph.D.	CEO, President & Director	861.24k	無	1972
Mr. Rodney K. B. Young	CFO, Principal Accounting Officer & Secretary	616.56k	無	1963
Dr. William Ho M.D., Ph.D.	Chief Medical Officer	620.32k	無	1966
Steve Young Ph.D.	Vice President of Technology	無	無	無
Dr. Dirk G. Brockstedt Ph.D.	Chief Scientific Officer	490.25k	無	1969
Mr. Michael Listgarten	General Counsel	無	無	無
Ms. Gwen R. Carscadden	Chief Human Resources Officer	無	無	1961
Dr. Paul Kassner	Senior Vice President of Quantitative & Computational Biology	無	無	1967
Dr. David Wustrow	Senior Vice President of Drug Discovery & Preclinical Development	無	無	1959
Ms. Jennifer Nicholson	Senior Vice President of Regulatory Affairs & Quality Assurance	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

公司管治

截至 2024年5月1日 止，RAPT Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：6；董事會：6；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。